Oncology

New preclinical data for InnoCare's ICP-B794 reveals a wider safety window and power to overcome drug resistance, positioning it as a top contender.

UK biotech Promatix presented a new AI-driven platform at AACR 2026 that finds thousands of new cancer targets, promising safer, more precise 'smart bomb' drugs.

With a $30M+ boost and a public market debut, Ionetix aims to scale its cyclotron tech for cancer therapy, diagnostics, and future energy solutions.

With £21M in funding, new Focused Research Organizations, Meridial and Echo Labs, aim to tackle major bottlenecks in neuroscience and ecological intelligence.

A Northeast Georgia cancer center joins an elite national group, offering a cutting-edge 'smart bomb' therapy that brings new hope closer to home for patients.

New preclinical data reveals a T cell engager targeting multiple cancer markers at once, a novel strategy to overcome immunotherapy's limits in solid tumors.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

New preclinical data reveals a novel drug, rinzimetostat, may overcome treatment resistance in prostate cancer by targeting a unique molecular switch.

New preclinical data shows SK Life Science Labs' protein degraders effectively target key drivers in prostate cancer, myeloma, and other hard-to-treat tumors.

New data reveals a novel cancer drug shrinks brain metastases in over half of small cell lung cancer patients, offering hope where options are scarce.

A new platform watches individual tumor cells to link behavior with biology, offering a powerful tool against treatment resistance in cancers like glioblastoma.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

New guidelines advise biennial screening for women 50-74 and caution for others, a move that has drawn sharp criticism from other medical bodies.

With global regulatory approvals secured, Gilead extends its tender offer for Arcellx, moving closer to acquiring a potential best-in-class CAR T therapy.

Preliminary Q1 data from Auna shows rising demand for specialized care in Peru, Colombia, and Mexico, offering investors a transparent new look.

A Korean biotech unveils a breakthrough by targeting the tumor's protective environment, a move that could make existing cancer drugs effective again.

San Diego's Blacksmith Medicines will present promising data on its FEN1 inhibitor, a new drug targeting a notoriously difficult class of enzymes.